PM
GYRE icon

Prosight Management’s Gyre Therapeutics GYRE Stock Holding History

Prosight Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40,224
Closed -$1.3M – 47
2020
Q3 		$1.3M Buy
40,224
+7,151
+22% +$280K 0.62% 36
2020
Q2 		$1.46M Sell
33,073
-17,980
-35% -$844K 0.63% 38
2020
Q1 		$1.67M Sell
51,053
-1,200
-2% -$55.1K 0.78% 31
2019
Q4 		$2.67M Sell
52,253
-22,168
-30% -$929K 1.17% 23
2019
Q3 		$2.74M Buy
74,421
+1,475
+2% +$79.5K 1.52% 22
2019
Q2 		$4.03M Buy
72,946
+8,386
+13% +$524K 2.03% 18
2019
Q1 		$3.93M Buy
64,560
+2,307
+4% +$148K 1.72% 25
2018
Q4 		$3.68M Buy
62,253
+30,712
+97% +$2.26M 1.9% 21
2018
Q3 		$2.55M Buy
+31,541
New +$2.5M 1.42% 25

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prosight Management's GYRE Position: Q4 2020 in Review

Prosight Management sold out of Gyre Therapeutics (GYRE) in Q4 2020, closing a stake of 40,224 shares — an estimated $1.3M sold.

Prosight Management first reported a position in GYRE in Q3 2018 and held it in 9 quarters. The position peaked at $4.03M in Q2 2019. 80 funds tracked by Wall St. Rank hold GYRE as of Q4 2020.

  • Prosight Management reported no remaining Gyre Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Prosight Management sold 40,224 Gyre Therapeutics shares in Q4 2020, an estimated $1.3M.
  • Prosight Management first reported a position in Gyre Therapeutics in Q3 2018 and held it in 9 quarters.
  • Prosight Management's Gyre Therapeutics position peaked at $4.03M in Q2 2019.
  • 80 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2020.

Based on Prosight Management's 13F filing for Q4 2020, filed 12 Feb 2021.